Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zomedica Pharmaceuticals (TSXV:ZOM) will delist its common shares from the TSX Venture Exchange, as of February 10th 2020.
  • This move is the result of the shares’ low trading value on the TSXV, and the high cost of maintaining a duel listing.
  • The company’s common shares will continue trading on the New York Stock Exchange American, which has represented 99% of Zomedica’s trading volume since January 2019.
  • Zomedica’s share price on the TSXV has remained unchanged, with shares trading at $0.31 apiece. Zomedica’s share price on the NYSE American has gone up 1.91 per cent, with shares trading at $0.24 apiece.

Veterinary diagnostic and pharmaceuticals company Zomedica (ZOM) has received approval to delist its common shares from the TSX Venture Exchange. This will take effect at close of business on February 10th 2020.

This move is due to low share trading value on the TSXV, and a reevaluation of the need for a dual listing.

Zomedica’s common shares will continue to be traded on the New York Stock Exchange American.

Since January 2019, trading on the NYSE American has represented roughly 99% of Zomedica’s trading volume, and is expected to continue being the primary source of capital.

The company’s Canadian shareholders will be able to continue trading shares on the NYSE American, under the code ZOM.

Zomedica’s share price on the TSXV has remained unchanged, with shares trading at $0.31 apiece. Zomedica’s share price on the NYSE American has gone up 1.91 per cent, with shares trading at $0.24 apiece.

More From The Market Herald
Featured Video Play Icon

" Sixth Wave (CSE:SIXW) announces rapid detection of E. Coli

Sixth Wave’s (SIXW) AMIPs prototype has detected E. Coli in as little as five minutes.

" Neovasc (TSX:NVCN) announces direct sales operations in the U.K.

Neovasc (NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022.
Lexagene Holdings - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) to host a webinar on the use of the MiQLab system to diagnose urinary tract infections

 LexaGene Holdings (LXG) and Dr. Jane Sykes will present a webinar entitled, “The Wave of the Future: In-Clinic PCR Diagnosis.”
BriaCell Therapeutics Corp

" BriaCell (TSX:BCT) partners with Waisman Biomanufacturing

BriaCell (BCT) has signed an agreement with Waisman Biomanufacturing to manufacture Bria-Pros for BriaCell’s anticipated clinical trial in advanced prostate cancer.